Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NV5O
|
|||
| Drug Name |
Finerenone
|
|||
| Synonyms |
UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho
Click to Show/Hide
|
|||
| Indication | Chronic kidney disease [ICD-11: GB61; ICD-10: N18, N18.9] | Approved | [1] | |
| Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 3 | [2] | ||
| Company |
Bayer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22N4O3
|
|||
| Canonical SMILES |
CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C
|
|||
| InChI |
1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
|
|||
| InChIKey |
BTBHLEZXCOBLCY-QGZVFWFLSA-N
|
|||
| CAS Number |
CAS 1050477-31-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mineralocorticoid receptor (MR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Aldosterone-regulated sodium reabsorption | |||
| Pathwhiz Pathway | Kidney Function | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215341. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.